Illustrative image – not actual.Piramal Enterprises' Pharma Solution division plans to invest Rs 248.4 crore in new equipment and next generation technologies.
The recent investments include areas such as Anti-body Drug Conjugation (ADC), Advanced Flow Reactor (ARF) and Biocatalysis Centre of Excellence systems.
Recently, the company completed a greenfield facility (Rs 62.1 crore) to double its Discovery Services capacity, and also approved a Rs 124.2 crore capacity expansion for Hormonal (Morpeth) and ADC (Grangemouth) manufacturing.
In addition to the investment of Rs 248.4 crore in new equipment and technologies, the company is also planning to augment related infrastructure.
Piramal Pharma Solutions has a successful record of over four decades in API supply (active pharmaceutical ingredients) drug products, drug discovery services, and supply of facilities in North America, Europe and Asia.
